Clinical Trials ArenaOriginal article
Akeso logs Phase III success in second tumour type for ivonescimab
Phase 3positiveivonescimabPositive
AI Analysis
Summary
Akeso reported Phase III success for ivonescimab in a second tumor type, with the drug currently under US review for non-small cell lung cancer.
Clinical Trial Data
Phase
Phase III
Primary Endpoint
Met
Outcome Details
Phase III success in second tumor type
Importance:7/10
Sentiment:
0.70
Phase IIIoncologysolid tumorsNSCLCpositive data
Read the original article
Published by Clinical Trials Arena on August 26, 2026 10:29 AM